ERBB2 and non-small cell lung carcinoma: Most clinical studies evaluating HER2-targeted therapies for NSCLCs have yielded disappointing results [14,15,16], and to this day, only patients with HER2-mutated NSCLC are eligible to receive anti-HER2 drugs.